



Monkeypox

Demographics of Patients Receiving TPOXX for Treatment of Monkeypox

Updated August 31, 2022

CDC, in partnership with FDA, has made it easier for healthcare providers to provide tecovirimat (TPOXX) treatment to patients with monkeypox under an expanded access Investigational New Drug (EA-IND) protocol. As of August 29, 2022, CDC has received and abstracted data from forms submitted on 1001 patients. However, this number underestimates the number of patients who are receiving TPOXX treatment as healthcare providers can start treatment before submitting IND paperwork to CDC. The table below shows the demographics of these 1001 patients who have received TPOXX and whose data have been analyzed.

Demographics	N (%)
Age, years (N=1001)	37.2 (median)
	0.5-80 (range)
Missing	35 (N/A)
Sex at birth (N=1001)	
Male	974 (98.4%)
Female	16 (1.6%)
Not reported	11 (N/A)
Race and ethnicity (N=1001)	
Asian, non-Hispanic	20 (2.4%)
Black, non-Hispanic	182 (22.2%)
White, non-Hispanic	303 (37.0%)
Hispanic	280 (34.1%)
Unknown Race, non-Hispanic	12 (1.5%)
Multiple Races, non-Hispanic	7 (0.9%)
Other, non-Hispanic	16 (2.0%)
Missing	181 (N/A)

Among the 1001 who have baseline IND paperwork, the median age was 37.2 years with a range of 0.5 to 80 years; white non-Hispanics were the largest represented racial and ethnic group. Among those that reported a sex at birth, 98.4% were male.

CDC has not received forms for every patient treated with TPOXX. There may be a lag in forms being submitted, so forms for patients treated recently may be more likely to be missing. Some sections of the submitted forms may also be incomplete. Therefore, these data may not reflect the overall population of patients who have received TPOXX.

As of August 29, 2022, CDC has received more than 1100 patient intake forms and has abstracted forms for 1001 individuals and clinical outcome forms for 539 individuals. Of the 539 patients with outcome forms, 198 included data during and post-treatment, 273 included data only during treatment, and 68 included data only post-treatment.

Page last reviewed: August 31, 2022